Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs 10X Genomics Inc (TXG) Price & Performance

MSTU trades at $1.87, down 1.06% with a bearish technical outlook showing 15 sell signals versus 1 buy signal. The ETF has experienced significant value erosion, with recent articles highlighting a 98% loss from November 2024 levels despite a 10:1 reverse stock split. Technical indicators show moving averages are unanimously bearish while oscillators remain neutral, with support and resistance clustered around $2.

The outlook remains challenging given the ETF's leveraged structure and substantial historical losses. Investment opportunity exists only for sophisticated traders comfortable with high volatility, while risks include daily rebalancing effects and continued erosion of value in declining markets. The fund's performance remains tightly coupled to its underlying asset's volatility.

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.